Wall Street Breakfast Eli Lilly sees weight loss pill success
Apr 17, 2025
Eli Lilly celebrates a successful trial for its weight loss pill, boosting stock confidence. Meanwhile, UnitedHealth struggles amid rising competition in the obesity drug market. Economic woes are highlighted as the European Central Bank adjusts interest rates in response to growth slowdowns. Apple shows resilience despite these challenges, and innovations like electric air taxis from Archer Aviation offer a glimpse into future travel. Expert predictions emphasize caution in navigating the unpredictable economic landscape.
AI Snips
Chapters
Transcript
Episode notes
Lilly's Breakthrough Diabetes Pill
- Eli Lilly's oral GLP-1 receptor agonist Orforglopron showed success in Phase 3 for type 2 diabetes.
- The pill reduced weight by about 8% and lowered A1c significantly in the trial.
UnitedHealth Cuts Year Outlook
- UnitedHealth Group slashed its full-year earnings outlook following weaker Q1 results.
- CEO Andrew Witte acknowledged growth but said performance didn't meet expectations.
ECB vs Fed Rate Policies Clash
- The European Central Bank cut rates again citing weakened growth outlook due to trade tensions.
- Donald Trump criticized Fed Chair Powell for not cutting rates similarly, calling for his termination.